Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NGLY1 deficiency Indication Strategy Report 2026: NGLY1, Trials and Deals
24 July 2026
2026 NGLY1 deficiency strategy: epidemiology, NGLY1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
MPI-congenital disorder of glycosylation Indication Strategy Report 2026: MPI, Trials and Deals
24 July 2026
2026 MPI-congenital disorder of glycosylation strategy: epidemiology, MPI biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XV Indication Strategy Report 2026: GYG1, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XV strategy: epidemiology, GYG1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XIII Indication Strategy Report 2026: ENO3, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XIII strategy: epidemiology, ENO3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XII Indication Strategy Report 2026: ALDOA, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XII strategy: epidemiology, ALDOA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XI Indication Strategy Report 2026: LDHA, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XI strategy: epidemiology, LDHA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type VI Indication Strategy Report 2026: PYGL, Trials and Deals
24 July 2026
2026 Glycogen storage disease type VI strategy: epidemiology, PYGL biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type 0 Indication Strategy Report 2026: GYS2, Trials and Deals
24 July 2026
2026 Glycogen storage disease type 0 strategy: epidemiology, GYS2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Delusional disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
24 July 2026
2026 Delusional disorder strategy: epidemiology, D2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Schizoaffective disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
24 July 2026
2026 Schizoaffective disorder strategy: epidemiology, D2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Seasonal affective disorder Indication Strategy Report 2026: SERT, Trials and Deals
24 July 2026
2026 Seasonal affective disorder strategy: epidemiology, SERT biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Circadian rhythm sleep-wake disorder Indication Strategy Report 2026: Melatonin receptor, Trials and Deals
24 July 2026
2026 Circadian rhythm sleep-wake disorder strategy: epidemiology, Melatonin receptor biology, clinical competition, recent deals, unmet need and market…